替加环素对艰难梭菌感染结局的影响：病例系列和倾向评分匹配回顾性研究。
Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.
机构信息
University of Virginiagrid.27755.32 School of Medicine, Charlottesville, Virginia, USA.
Division of Infectious Diseases & International Health, Department of Medicine, University of Virginiagrid.27755.32 School of Medicine, Charlottesville, Virginia, USA.
出版信息
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0000122. doi: 10.1128/aac.00001-22. Epub 2022 Jun 1.
This case series and propensity-matched cohort study on the use of tigecycline in Clostridioides difficile infection (CDI) evaluated the effect of tigecycline on 30-day mortality. Adjusted for ATLAS Score, hypotension, treatment time period, and serum lactate, tigecycline did not significantly improve 30-day mortality (odds ratio: 0.89; 95% confidence interval: 0.25-3.12; 0.853). A randomized controlled trial is needed to determine efficacy and safety of tigecycline in severe or refractory CDI.
本病例系列和倾向评分匹配队列研究评估了替加环素在艰难梭菌感染（CDI）中的应用对 30 天死亡率的影响。调整 ATLAS 评分、低血压、治疗时间段和血清乳酸后，替加环素并未显著改善 30 天死亡率（比值比：0.89；95%置信区间：0.25-3.12；0.853）。需要进行随机对照试验来确定替加环素在严重或难治性 CDI 中的疗效和安全性。
Zotero 插件